tirzepatide nad The science behind Tirzepatide… and why it works 👇 isn't just about weight loss—it's a dual-action medication that targets key hormones involved in metabolism and appetite regulation. Here's what's happening in Tirzepatide and other GLP1RA as

And across all comparisons, most GI events are mild to moderate in severity, transient, and concentrated during dose escalation periods

In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration (2.3)]

The FDA approved tirzepatide only as a subcutaneous injection, first as Mounjaro for type 2 diabetes in May 2022, then as Zepbound for chronic weight management in November 2023

Participants had a mean baseline starting weight of 226-231 lbs

Weekly weight trend: Your weight loss results should not change based on injection timing

Patients whose plans do cover these medications for weight loss indications may still need you to submit a prior authorization request on their behalf